Compare iShares MSCI Germany (DAX) (EWG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI Germany (DAX) trades at $41.18, while Vertex Pharmaceuticals Incorporated trades at $482.07 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| EWG | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $529.59 |
52-Week Low | $38.08 | $366.54 |
Market Cap | — | $121.09B |
Enterprise Value | — | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.10, down 0.7% on the day, with a neutral technical signal and bearish moving averages. Key support is at $41 and resistance at $42. The stock lacks available financial ratios, and a dividend of $0.83 is scheduled for June 2026. Recent news highlights German economic policies and ECB rate decisions influencing European market sentiment.
The outlook is cautious due to limited fundamental data and mixed technical indicators. Risks include macroeconomic volatility from energy prices and ECB policy shifts. Analyst sentiment is neutral, with no clear consensus on price targets or ratings available.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
